ClinicalTrials.gg
CompletedNCT02389816Updated Mar 24, 2021Results posted

A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

A Phase 3 interventional study of Placebo and Vortioxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 47 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
21st of 54
493 · median 413
Started
2015
with 2 others
Phase 3
31 of 54
1 open now
Registered
31st of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 21st largest by enrollment, is one of 3 that started in 2015, is one of 31 in phase 3, and was the 31st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, parallel-group, phase III study to assess the efficacy and safety of 8-week treatment of two fixed doses of Vortioxetine (Lu AA21004; 10 or 20 mg/day) in Japanese participants with major depressive disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, form prior to the initiation of any study procedures.
  3. The participant suffers from recurrent MDD as the primary diagnosis according to , 4th Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.3x).
  4. The participant is a man or a woman aged 20 to 75 years (both inclusive) at the time of informed consent.
  5. The reported duration of the current major depressive episode is 3 to 12 months (both inclusive) at the start of screening period.
  6. The participant has a MADRS total score ≥26, Hamilton Depression Rating Scale (HAM-D17) total score ≥18, and Clinical global impression scale-Severity (CGI-S) score ≥4 at the start of screening period, at the start of placebo lead-in period and at the start of double-blind treatment period.
  7. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent to the end of the follow-up period.

Exclusion criteria

Exclusion Criteria:

  1. The participant has any following current or past history of psychiatric disorder and/or neurological disorder:

    • Any current psychiatric disorder other than MDD as defined by (To be assessed by Mini International Neuropsychiatric Interview: MINI). A participant who exhibits symptoms of anxiety is eligible unless the participant fulfills the diagnostic criteria for a current anxiety disorder per DSM-IV-TR.
    • Current diagnosis or history of manic, mixed or hypomanic episode, MDD with psychotic features, schizophrenia or any other psychotic disorder (including substance-related mental disorders, or mental disorders due to a general medical condition) as defined by DSM-IV-TR.
    • Current diagnosis or history of any substance-related disorder (except nicotine and caffeine-related disorders) as defined by DSM-IV-TR.
    • The participant with a positive urine drug screening result at the start of screening period or the start of placebo lead-in period. In case that a participant showed positive test result at the start of screening period because the test was conducted before washout of pretreatment drug, the participant is eligible as long as he/she shows negative result at the start of placebo lead-in period.
    • Presence or history of any neurological disorder (including epilepsy).
    • Any neurodegenerative disorder (e.g. Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease).
    • Any DSM-IV-TR axis II disorder.
  2. The participant has the current or previous major depressive episode which was considered by the investigator or sub-investigator to have been resistant to 2 or more adequate antidepressants treatments of at least 6 weeks duration each at sufficient doses.
  3. The participant has received any augmentation therapy (e.g. lithium, T3/T4, lamotrigine, sodium valproate, carbamazepine, additional atypical antipsychotic, or concomitant use of other antidepressant, etc.) for the current major depressive episode.
  4. In the opinion of the investigator or sub-investigator, the participant has experienced significant number of major depressive episodes in the past, and is suspected of disease other than MDD.
  5. In the opinion of the investigator or sub-investigator, the participant has experienced the first major depressive episode at his/her young age, and is suspected of disease other than MDD.
  6. The participant has a MADRS total score at the start of double-blind treatment period that has improved or aggravated by 25% or more from the score at the start of placebo lead-in period.
  7. The participant is significantly non-compliant with the study drug in the placebo lead-in period; e.g., not taking the study drug for 6 or more consecutive days.
  8. The participant has received electroconvulsive therapy, vagus nerve stimulation, or repetitive transcranial magnetic stimulation therapy within 6 months prior to the screening period, or plans to initiate such therapy during the study.
  9. The participant is receiving cognitive-behavioral therapy or psychotherapy at the time of , or plans to initiate such therapy during the study.
  10. The participant is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal thoughts) of the MADRS at the start of screening period, at the start of placebo lead-in period or at the start of double-blind treatment period, or has attempted suicide within 6 months prior to the start of screening period.
  11. The participant has experienced any environmental change (e.g. temporary retirement, returnment, change of residence) considered by the investigator or sub-investigator to have the potential to impact on the efficacy evaluation, or plans such environmental changes during the study.
  12. The participant is currently receiving drug therapy for thyroid dysfunction.
  13. The participant is currently receiving hormonal therapy for gynecological disease.
  14. The participant has taken excluded medications during the protocol-specified period, or will require to take excluded medications during the study.
  15. The participant has previously received vortioxetine.
  16. The participant has received study drug in a previous clinical study of Lu AA21004 (including this study).
  17. The participant has a clinically significant chronic liver disease.
  18. The participant has a history of severe allergy or to drugs.
  19. The participant has a clinically significant unstable illness, for example, liver disorder or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, neoplastic, skin and subcutaneous tissue disorders, eye disorders, or metabolic disturbance.
  20. The participant has clinically significant abnormal vital signs as determined by the investigator or sub-investigator at the start of screening period, placebo lead-in period, or double-blind treatment period.
  21. The participant has clinically significant abnormal (ECG) as determined by the investigator or sub-investigator, at the start of the screening period, at the start of placebo lead-in period, or at the start of double-blind treatment period.
  22. The participant has clinically significant abnormal findings of clinical laboratory tests as determined by the investigator or sub-investigator, or has (ALT) or aspartate aminotransferase (AST) >2 × at the start of screening period or at the start of placebo lead-in period.
  23. If female, the participant is pregnant or lactating.
  24. The participant has a disease or takes medications that could, in the opinion of the investigator or sub-investigator, interfere with the evaluation of the safety, tolerability, or efficacy.
  25. The participant is, in the opinion of the investigator or sub-investigator, unsuitable for this study for any other reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
493 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo tablets, orally, once daily for up to Week 8

    Drug: Placebo

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg tablets, orally, once daily for up to Week 8

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 20 mg

    Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8

    Drug: Vortioxetine

Interventions

  • DrugPlacebo

    Placebo tablets

  • Vortioxetine tablets

    Also known as: Lu AA21004

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

    Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks

Secondary outcomes

  1. MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))

    Reported data was percentage of participants who met MADRS response criteria (defined as a ≥50% decrease in the MADRS total score from Baseline) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

    Time frame: Week 8

  2. MADRS Remission at Week 8 (LOCF)

    Reported data was percentage of participants who met MADRS remission criteria (defined as a MADRS total score ≤10) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

    Time frame: Week 8

  3. Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)

    The HAM-D17 is a clinician-rated scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 where a higher score indicates a greater depressive state.

    Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks

  4. Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)

    The CGI-I assesses the participant's state of mental illness improvement. The participant's condition compared to baseline is rated on a seven-point scale (1=very much improved \~ 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms.

    Time frame: Week 8

  5. Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)

    The CGI-S assesses the impression of the participant's current state of mental illness. The current severity of mental illness is rated on a seven-point scale (1=normal, not ill at all \~ 7=most extremely ill) based on a total clinical experience. Higher scores indicate greater severity of mental illness.

    Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks

  6. Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)

    The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

    Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks

  7. Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)

    The DSST is a neuropsychological test to assess cognitive function. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function.

    Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks

  8. Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)

    PDQ-5 is a self-administered 5-item questionnaire to assess cognition function, including subscales of attention/concentration, retrospective memory, prospective memory, and planning/organization. PDQ-5 total score ranges from 0 to 20 with smaller scores indicate greater cognitive function.

    Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks

07

Results

Posted Jun 26, 2019

Participant flow

Participants took part in the study at 64 investigative sites in Japan, from 10 April 2015 to 16 March 2018.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 10 mgVortioxetine 20 mg
Started164165164
Completed149152152
Not completed151312
Withdrew: Randomized but not treated100
Withdrew: Pretreatment event or adverse event (ae)467
Withdrew: Major protocol deviation100
Withdrew: Lost to follow-up100
Withdrew: Withdrawal of consent644
Withdrew: Lack of efficacy100
Withdrew: Non compliance with study drug111
Withdrew: Reason not specified020

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

Time frame:
Baseline (At the start of double-blind treatment period), up to 8 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8-12.37 ± 0.714-15.03 ± 0.699-15.45 ± 0.705
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0080 · Least square (ls) mean difference: -2.66 · 95% CI -4.63 to -0.70Mixed Models for Repeated Measures (MMRM)
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0023 · Ls mean difference: -3.07 · 95% CI -5.05 to -1.10Mixed Models for Repeated Measures (MMRM)
SecondaryMADRS Response at Week 8 (Last Observation Carried Forward (LOCF))

Reported data was percentage of participants who met MADRS response criteria (defined as a ≥50% decrease in the MADRS total score from Baseline) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))
Percentage of ParticipantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))36.647.950.6
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.0341 · Odds ratio (or): 1.621 · 95% CI 1.037 to 2.533
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.0110 · Odds ratio (or): 1.788 · 95% CI 1.143 to 2.799
SecondaryMADRS Remission at Week 8 (LOCF)

Reported data was percentage of participants who met MADRS remission criteria (defined as a MADRS total score ≤10) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
MADRS Remission at Week 8 (LOCF)
Percentage of ParticipantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
MADRS Remission at Week 8 (LOCF)21.132.130.9
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.0186 · Odds ratio (or): 1.839 · 95% CI 1.107 to 3.054
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.0418 · Odds ratio (or): 1.700 · 95% CI 1.020 to 2.834
SecondaryChange From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)

The HAM-D17 is a clinician-rated scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 where a higher score indicates a greater depressive state.

Time frame:
Baseline (At the start of double-blind treatment period), up to 8 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)-8.38 ± 0.541-10.19 ± 0.524-10.17 ± 0.532
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0165 · Ls mean difference: -1.81 · 95% CI -3.290 to -0.332
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.0190 · Ls mean difference: -1.79 · 95% CI -3.278 to -0.295
SecondaryClinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)

The CGI-I assesses the participant's state of mental illness improvement. The participant's condition compared to baseline is rated on a seven-point scale (1=very much improved \~ 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms.

Time frame:
Week 8
Reported as:
Least squares mean · Scores on a scale
Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)2.77 ± 0.0852.42 ± 0.0842.38 ± 0.085
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0031 · Ls mean difference: -0.36 · 95% CI -0.590 to -0.121
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.0011 · Ls mean difference: -0.39 · 95% CI -0.629 to -0.158
SecondaryChange From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)

The CGI-S assesses the impression of the participant's current state of mental illness. The current severity of mental illness is rated on a seven-point scale (1=normal, not ill at all \~ 7=most extremely ill) based on a total clinical experience. Higher scores indicate greater severity of mental illness.

Time frame:
Baseline (At the start of double-blind treatment period), up to 8 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)-1.19 ± 0.0088-1.42 ± 0.0087-1.48 ± 0.0087
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0609 · Ls mean difference: -0.23 · 95% CI -0.474 to 0.011
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.0179 · Ls mean difference: -0.29 · 95% CI -0.537 to -0.051
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)

The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

Time frame:
Baseline (At the start of double-blind treatment period), up to 8 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)-2.85 ± 0.447-4.20 ± 0.432-4.43 ± 0.440
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0311 · Ls mean difference: -1.34 · 95% CI -2.564 to -0.122
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.0126 · Ls mean difference: -1.57 · 95% CI -2.807 to -0.339
SecondaryChange From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)

The DSST is a neuropsychological test to assess cognitive function. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function.

Time frame:
Baseline (At the start of double-blind treatment period), up to 8 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)4.92 ± 0.6324.13 ± 0.6284.80 ± 0.629
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.3793 · Ls mean difference: -0.79 · 95% CI -2.539 to 0.968
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.9011 · Ls mean difference: -0.11 · 95% CI -1.862 to 1.641
SecondaryChange From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)

PDQ-5 is a self-administered 5-item questionnaire to assess cognition function, including subscales of attention/concentration, retrospective memory, prospective memory, and planning/organization. PDQ-5 total score ranges from 0 to 20 with smaller scores indicate greater cognitive function.

Time frame:
Baseline (At the start of double-blind treatment period), up to 8 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)
Scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)-1.41 ± 0.234-2.28 ± 0.231-2.69 ± 0.234
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0089 · Ls mean difference: -0.87 · 95% CI -1.512 to -0.218
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.0001 · Ls mean difference: -1.27 · 95% CI -1.922 to -0.619

Adverse events

Collected over Up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/161 (0%)1/161 (0.6%)32/161 (19.9%)
Vortioxetine 10 mg0/165 (0%)1/165 (0.6%)54/165 (32.7%)
Vortioxetine 20 mg2/163 (1.2%)3/163 (1.8%)51/163 (31.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 10 mgVortioxetine 20 mg
NephrolithiasisRenal and urinary disorders1/1610/1650/163
Anaesthetic complicationInjury, poisoning and procedural complications0/1610/1651/163
Subarachnoid haemorrhageInjury, poisoning and procedural complications0/1610/1651/163
Cerebral haemorrhageNervous system disorders0/1610/1651/163
Altered state of consciousnessNervous system disorders0/1611/1650/163
Most frequent other events
Most frequent other events
EventPlaceboVortioxetine 10 mgVortioxetine 20 mg
NasopharyngitisInfections and infestations26/16123/16521/163
NauseaGastrointestinal disorders1/16121/16525/163
SomnolenceNervous system disorders6/1617/16511/163
VomitingGastrointestinal disorders0/1619/1656/163

Baseline characteristics

Randomized Set, Randomized set was defined as all participants who randomized in this study.

Age, Continuous
Age, Continuous(Years)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean39.5 ± 10.4740.0 ± 10.5840.4 ± 11.3140.0 ± 10.78
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Female727280224
Male929384269
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(Participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Japan164165164493
Height
Height(Centimeters (cm))PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean166.5 ± 8.51165.2 ± 9.04164.5 ± 7.86165.4 ± 8.51
Weight
Weight(Kilograms (kg))PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean62.44 ± 12.21861.97 ± 12.95861.54 ± 12.00661.98 ± 12.382
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean22.44 ± 3.45022.56 ± 3.56022.65 ± 3.59422.55 ± 3.530
Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
Montgomery Åsberg Depression Rating Scale (MADRS) Total Score(Scores on a scale)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean30.5 ± 3.8730.8 ± 3.7330.6 ± 3.6230.6 ± 3.73

5 further baseline measures are reported on the registry.

08

Study locations

47 sites
  • Nagoya, Aichi, Japan
  • Nagareyama, Chiba, Japan
  • Noda, Chiba, Japan
  • Iizuka, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Kurume, Fukuoka, Japan
  • Koriyama, Fukushima, Japan
  • Shirakawa, Fukushima, Japan
  • Sapporo, Hokkaido, Japan
  • Ashiya, Hyogo, Japan
  • Kanazawa, Ishikawa, Japan
  • Kawasaki, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Yokosuka, Kanagawa, Japan
  • Kurashiki, Okayama, Japan
  • Kadoma, Osaka, Japan
  • Kita-ku, Osaka, Japan
  • Osakasayama, Osaka, Japan
  • Sakai, Osaka, Japan
  • Karatsu, Saga, Japan
  • Kawagoe, Saitama, Japan
  • Kusatsu, Shiga, Japan
  • Anan, Tokushima, Japan
  • Arakawa-ku, Tokyo, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Hachioji, Tokyo, Japan
  • Itabashi-ku, Tokyo, Japan
  • Katsushika-ku, Tokyo, Japan
  • Koto-ku, Tokyo, Japan
  • Meguro-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Mitaka, Tokyo, Japan
  • Musashino, Tokyo, Japan
  • Nakano-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shibuya-ku, Tokyo, Japan
  • Shinagawa-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Suginami-ku, Tokyo, Japan
  • Taito-ku, Tokyo, Japan
  • Toshima-ku, Tokyo, Japan
  • Kofu, Yamanashi, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Kumamoto, Japan
  • Okayama, Japan
  • Saitama, Japan
09

References and documents

Publications

  • Watanabe K, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Inoue T. Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. Neuropsychiatr Dis Treat. 2022 Feb 19;18:363-373. doi: 10.2147/NDT.S340281. eCollection 2022. PubMed 35221687 ↗
  • Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K. Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. Neuropsychiatr Dis Treat. 2021 Dec 21;17:3781-3790. doi: 10.2147/NDT.S335028. eCollection 2021. PubMed 34992372 ↗
  • Inoue T, Fujimoto S, Marumoto T, Kitagawa T, Ishida K, Nakajima T, Moriguchi Y, Fujikawa K, Watanabe K. Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. Neuropsychiatr Dis Treat. 2021 Dec 18;17:3735-3741. doi: 10.2147/NDT.S340309. eCollection 2021. PubMed 34955641 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Mar 2018, 35 months.

Results were first posted in Jun 2019, 1 year 3 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 35 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2015
First posted
Mar 17, 2015
StartActual
Apr 10, 2015
Primary completionActual
Mar 16, 2018
CompletionActual
Mar 16, 2018
Results first posted
Jun 26, 2019
Last update
Mar 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02389816
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Apr 10, 2015
Primary completion
Mar 16, 2018
Completion
Mar 16, 2018
Results posted
Jun 26, 2019
Last update
Mar 24, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion